Biotechnology laboratory where artificial intelligence designs therapeutic antibodies, featuring DNA helices, glowing neural-network interfaces, hair follicle imagery, and an upward stock chart symbolizing Absci's AI-powered drug discovery platform.

🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.

When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.

Read entire article

An illustration of Adobe's headquarters transformed into a futuristic creative studio. A confident businessman resembling Eli Lilly CEO David Ricks enthusiastically purchases giant glowing Adobe shares while smiling AI robots help artists create.

🎨 Adobe (ADBE) Stock Analysis: Why Eli Lilly CEO David Ricks Just Bought $1.9 Million of Adobe Stock

Wall Street says AI threatens Adobe. The numbers tell a different story. Revenue keeps hitting records, AI recurring revenue has tripled, valuation has collapsed to multi-year lows, and Eli Lilly CEO David Ricks just invested another $1.9 million of his own money. Here's why Adobe may deserve another look.

Read entire article